Cargando…
Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed u...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957040/ https://www.ncbi.nlm.nih.gov/pubmed/36833140 http://dx.doi.org/10.3390/healthcare11040607 |
_version_ | 1784894727218266112 |
---|---|
author | Rabie, Al Shaimaa Ibrahim Salah, Hager Said, Amira S. A. Shaaban, Ahmed Hassan Abdou, Lamya Mohamed Khalil, Doaa Mahmoud Kharaba, Zelal Afifi, Hala Sofy, Mahmoud R. Youssef, Eman M. I. Bayoumy, Eman S. M. Hussein, Raghda R. S. |
author_facet | Rabie, Al Shaimaa Ibrahim Salah, Hager Said, Amira S. A. Shaaban, Ahmed Hassan Abdou, Lamya Mohamed Khalil, Doaa Mahmoud Kharaba, Zelal Afifi, Hala Sofy, Mahmoud R. Youssef, Eman M. I. Bayoumy, Eman S. M. Hussein, Raghda R. S. |
author_sort | Rabie, Al Shaimaa Ibrahim |
collection | PubMed |
description | There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed up the process of clinical benefit, lower the risk of death, and avert the need for ventilators. This randomized controlled trial (RCT) studied patients with a proven infection of SARS-CoV-2 and hyperinflammatory reactions. The inclusion criteria included fever (body temperature > 38 °C), pulmonary infiltrates, or supplemental oxygen. The patients received either conventional treatment with one dose of either tocilizumab (8 mg per kilogram of body weight) or conventional treatment only. The subjects were randomized to receive either treatment with a 1:1 ratio. A time-to-event test was conducted to determine the time to intubation or death. There was an insignificant difference between the investigated groups regarding the time to death, time to mechanical ventilation, and percentage of deaths. The conventional group’s median (IQR) hospital length of stay was 4 (3–6) days, whereas the tocilizumab therapy group was 7 (4.75–10) days. There was a substantial difference in the mechanical ventilation rates in both groups, which were 17 (34%) and 28 (56%), respectively. In hospitalized patients with severe illness and COVID-19, tocilizumab was ineffective in preventing intubation or death. Trials must be larger, however, in order to exclude the potential benefits or harms. |
format | Online Article Text |
id | pubmed-9957040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99570402023-02-25 Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection Rabie, Al Shaimaa Ibrahim Salah, Hager Said, Amira S. A. Shaaban, Ahmed Hassan Abdou, Lamya Mohamed Khalil, Doaa Mahmoud Kharaba, Zelal Afifi, Hala Sofy, Mahmoud R. Youssef, Eman M. I. Bayoumy, Eman S. M. Hussein, Raghda R. S. Healthcare (Basel) Article There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed up the process of clinical benefit, lower the risk of death, and avert the need for ventilators. This randomized controlled trial (RCT) studied patients with a proven infection of SARS-CoV-2 and hyperinflammatory reactions. The inclusion criteria included fever (body temperature > 38 °C), pulmonary infiltrates, or supplemental oxygen. The patients received either conventional treatment with one dose of either tocilizumab (8 mg per kilogram of body weight) or conventional treatment only. The subjects were randomized to receive either treatment with a 1:1 ratio. A time-to-event test was conducted to determine the time to intubation or death. There was an insignificant difference between the investigated groups regarding the time to death, time to mechanical ventilation, and percentage of deaths. The conventional group’s median (IQR) hospital length of stay was 4 (3–6) days, whereas the tocilizumab therapy group was 7 (4.75–10) days. There was a substantial difference in the mechanical ventilation rates in both groups, which were 17 (34%) and 28 (56%), respectively. In hospitalized patients with severe illness and COVID-19, tocilizumab was ineffective in preventing intubation or death. Trials must be larger, however, in order to exclude the potential benefits or harms. MDPI 2023-02-17 /pmc/articles/PMC9957040/ /pubmed/36833140 http://dx.doi.org/10.3390/healthcare11040607 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rabie, Al Shaimaa Ibrahim Salah, Hager Said, Amira S. A. Shaaban, Ahmed Hassan Abdou, Lamya Mohamed Khalil, Doaa Mahmoud Kharaba, Zelal Afifi, Hala Sofy, Mahmoud R. Youssef, Eman M. I. Bayoumy, Eman S. M. Hussein, Raghda R. S. Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection |
title | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection |
title_full | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection |
title_fullStr | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection |
title_full_unstemmed | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection |
title_short | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection |
title_sort | clinical consequences for individuals treated with tocilizumab for serious covid-19 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957040/ https://www.ncbi.nlm.nih.gov/pubmed/36833140 http://dx.doi.org/10.3390/healthcare11040607 |
work_keys_str_mv | AT rabiealshaimaaibrahim clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT salahhager clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT saidamirasa clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT shaabanahmedhassan clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT abdoulamyamohamed clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT khalildoaamahmoud clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT kharabazelal clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT afifihala clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT sofymahmoudr clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT youssefemanmi clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT bayoumyemansm clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection AT husseinraghdars clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection |